RNA-Binding Competition Therapy for TDP-43 Cross-Seeding

Target: TARDBP Composite Score: 0.374 Price: $0.38▼3.4% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🟢 Parkinson's Disease 🧠 Neurodegeneration

🏆 ChallengeSolve: RNA binding protein dysregulation across ALS FTD and AD$119K bounty →

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.374

Top 83% of 561 hypotheses

T3 Provisional

Single-source or model-inferred

Needs composite score ≥0.60 (current: 0.37) for Supported

C+ Mech. Plausibility 15% 0.50 Top 79%

C Evidence Strength 15% 0.40 Top 82%

A Novelty 12% 0.85 Top 34%

D Feasibility 12% 0.25 Top 92%

C Impact 12% 0.45 Top 93%

D Druggability 10% 0.30 Top 85%

D Safety Profile 8% 0.25 Top 95%

B+ Competition 6% 0.75 Top 47%

D Data Availability 5% 0.35 Top 94%

D Reproducibility 5% 0.30 Top 91%

Evidence

9 supporting | 3 opposing

Citation quality: 100%

Debates

2 sessions B

Avg quality: 0.68

Convergence

0.58 C+ 3 related hypothesis share this target

From Analysis:

Protein aggregation cross-seeding across neurodegenerative diseases

Protein aggregation cross-seeding across neurodegenerative diseases?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Transglutaminase-2 Cross-Linking Inhibition Strategy

Score: 0.488 | Target: TGM2

Glycosaminoglycan Template Disruption Approach

Score: 0.464 | Target: HSPG2

TREM2-Mediated Selective Aggregate Clearance Pathway

Score: 0.430 | Target: TREM2

HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor

Score: 0.420 | Target: DNAJB6

Liquid-Liquid Phase Separation Modifier Therapy

Score: 0.416 | Target: G3BP1

Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption

Score: 0.384 | Target: PHB2

→ View full analysis & all 7 hypotheses

Description

Background and Rationale

...

Background and Rationale

TAR DNA-binding protein 43 (TDP-43), encoded by the TARDBP gene, is a heterogeneous nuclear ribonucleoprotein (hnRNP) that plays critical roles in RNA processing, including transcription, splicing, transport, and stability regulation. Under pathological conditions, TDP-43 undergoes cytoplasmic mislocalization, hyperphosphorylation, ubiquitination, and aggregation, forming characteristic inclusions observed in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and increasingly recognized in Alzheimer's disease and other neurodegenerative disorders. Recent evidence suggests that TDP-43 proteinopathy may not exist in isolation but rather facilitates cross-seeding mechanisms that promote the aggregation of other pathological proteins, including tau and α-synuclein. This cross-seeding phenomenon represents a critical intersection in the pathogenesis of multiple neurodegenerative diseases, potentially explaining the frequent co-occurrence of mixed pathologies in aging brains. The RNA-binding competition therapy hypothesis proposes that synthetic RNA aptamers could be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs. This therapeutic strategy leverages the unique molecular properties of TDP-43's RNA-binding domains to prevent the formation of pathological RNA-protein complexes that serve as scaffolds for cross-seeding events.

Proposed Mechanism

TDP-43 contains two highly conserved RNA recognition motifs (RRM1 and RRM2) and a glycine-rich C-terminal domain that mediates protein-protein interactions. Under physiological conditions, TDP-43 binds to specific RNA sequences, particularly UG-rich and GU-rich motifs, through its RRMs. However, in pathological states, cytoplasmic TDP-43 can aberrantly interact with mRNAs encoding tau and α-synuclein, forming ribonucleoprotein complexes that serve as nucleation sites for protein aggregation. The proposed mechanism involves the design of high-affinity synthetic RNA aptamers that would competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets. These aptamers would be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX). By saturating TDP-43's RNA-binding capacity with these synthetic competitors, the aptamers would prevent TDP-43 from binding to tau and α-synuclein mRNAs, thereby disrupting the formation of pathological RNA scaffolds. Additionally, the aptamers could be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities. The competition would effectively sequester cytoplasmic TDP-43 away from its pathological RNA partners while potentially promoting its nuclear relocalization or degradation through targeted mechanisms.

Supporting Evidence

Several lines of evidence support the feasibility and rationale of this therapeutic approach. First, studies by Gasset-Rosa et al. (2019) demonstrated that TDP-43 can form phase-separated ribonucleoprotein granules that recruit tau mRNA, leading to local tau protein synthesis and aggregation. This work established the direct mechanistic link between TDP-43 RNA binding and tau pathology. Similarly, research by Buratti and colleagues has shown that TDP-43 can bind to α-synuclein mRNA 3'-UTR regions, influencing α-synuclein protein levels and aggregation propensity. The success of RNA aptamer therapeutics in other contexts provides additional support; for example, pegaptanib (Macugen) was the first FDA-approved RNA aptamer drug, demonstrating the clinical viability of this approach. Furthermore, studies by Polymenidou et al. (2011) using CLIP-seq technology revealed that TDP-43 has thousands of RNA targets in the brain, many of which encode proteins involved in synaptic function and neurodegeneration. The competitive binding principle has been validated in other systems; for instance, Bose et al. (2008) showed that synthetic RNA decoys could effectively compete with natural targets for protein binding. Additionally, recent work by Mann et al. (2019) demonstrated that stabilizing TDP-43-RNA interactions could prevent TDP-43 aggregation, suggesting that appropriately designed RNA molecules could modulate TDP-43 pathology. The co-occurrence of TDP-43 pathology with tau and α-synuclein inclusions in human brain tissue, as documented by numerous neuropathological studies, provides clinical relevance for targeting these cross-seeding mechanisms.

Experimental Approach

The experimental validation of this hypothesis would require a multi-phase approach combining in vitro biochemical assays, cellular models, and ultimately in vivo studies. Initially, SELEX would be employed to identify high-affinity RNA aptamers against purified recombinant TDP-43 RRM domains. Selected aptamers would be characterized using surface plasmon resonance or isothermal titration calorimetry to determine binding affinities and kinetics. Competitive binding assays would test the ability of aptamers to displace TDP-43 from tau and α-synuclein mRNA targets using electrophoretic mobility shift assays and fluorescence polarization. Cellular studies would utilize primary neurons or differentiated induced pluripotent stem cell-derived neurons expressing pathological TDP-43 variants. Aptamer delivery could be achieved through transfection, electroporation, or advanced delivery systems like lipid nanoparticles. Immunofluorescence microscopy would assess TDP-43 subcellular localization, while co-immunoprecipitation experiments would evaluate disruption of TDP-43-RNA complexes. Protein aggregation would be monitored using biochemical fractionation, thioflavin-T staining, and transmission electron microscopy. In vivo validation would employ transgenic mouse models expressing mutant TDP-43, such as the TDP-43A315T or TDP-43G348C lines, with aptamer delivery via intracerebroventricular injection or advanced delivery systems. Behavioral assessments, neuropathological analysis, and biochemical evaluation of protein aggregation would determine therapeutic efficacy. Additionally, RNA sequencing would assess off-target effects on the transcriptome.

Clinical Implications

This therapeutic approach offers several significant advantages for treating neurodegenerative diseases. By targeting the RNA-mediated cross-seeding mechanism, it could potentially address multiple pathologies simultaneously, making it particularly valuable for treating mixed dementia cases where TDP-43, tau, and α-synuclein pathologies coexist. The specificity of RNA aptamers could minimize off-target effects compared to small molecule approaches, potentially reducing side effects. Furthermore, this strategy could be particularly effective in early disease stages when cross-seeding mechanisms are actively promoting pathology spread. The therapeutic could be delivered through various routes, including intrathecal injection or potentially through blood-brain barrier-penetrating delivery systems. For ALS patients, where TDP-43 pathology is nearly universal, this approach could slow disease progression by preventing the recruitment of additional pathological proteins. In FTD cases with TDP-43 pathology, the therapy could potentially prevent the development of concurrent Alzheimer's-type pathology. The modular nature of RNA aptamers also allows for potential combination therapies, where different aptamers could target distinct aspects of TDP-43 pathology or be combined with other therapeutic modalities. Additionally, the approach could serve as a valuable research tool for dissecting the role of RNA-mediated cross-seeding in disease progression.

Challenges and Limitations

Several significant challenges must be addressed for this therapeutic approach to succeed. First, delivery of RNA aptamers to the brain remains a major hurdle, as naked RNA is rapidly degraded and has poor blood-brain barrier penetration. Chemical modifications such as 2'-fluoro or 2'-O-methyl substitutions could improve stability, but may alter binding specificity. The blood-brain barrier penetration issue would likely require advanced delivery systems, potentially increasing complexity and cost. Second, the physiological functions of TDP-43 must be preserved; complete sequestration of TDP-43 could disrupt essential RNA processing functions, leading to toxicity. Achieving the right balance between pathological inhibition and physiological preservation would require careful dose optimization. Third, competing hypotheses exist regarding TDP-43 pathology mechanisms, including loss-of-function models where cytoplasmic TDP-43 aggregation depletes nuclear TDP-43 function. If loss-of-function is the primary mechanism, sequestering TDP-43 might exacerbate pathology. Fourth, the heterogeneity of TDP-43 pathology across different diseases and even within individual patients could complicate therapeutic design. Fifth, potential compensatory mechanisms might emerge, where other RNA-binding proteins could substitute for TDP-43 in cross-seeding processes. Finally, the long development timeline for RNA therapeutics and the need for specialized manufacturing and storage conditions could limit clinical translation. Despite these challenges, the growing success of RNA therapeutics in other diseases and the urgent need for effective neurodegeneration treatments make this approach worthy of continued investigation.

Quantitative Evidence Chain and Key Citations

TDP-43 as a cross-seeding hub in neurodegeneration:

TDP-43 pathology co-occurs with other proteinopathies in 30-50% of AD cases (PMID: 25107630, Josephs et al., Acta Neuropathol 2014), 50-70% of FTLD-tau cases, and 15-25% of PD cases. This high comorbidity rate suggests active cross-seeding rather than coincidental co-occurrence.
TDP-43's RNA-recognition motifs (RRM1 and RRM2, aa 106-259) serve dual roles: RNA binding for normal function AND liquid-liquid phase separation (LLPS) that seeds pathological aggregation. The phase-separated TDP-43 condensates recruit other aggregation-prone proteins (tau, FUS, hnRNPA1) through heterotypic interactions in the glycine-rich low-complexity domain (PMID: 30420683, Gasset-Rosa et al., Neuron 2019).
In vitro cross-seeding kinetics: TDP-43 C-terminal fragments (CTFs, aa 274-414) accelerate tau (0N4R) aggregation by reducing the lag phase from 72h to 18h at 10:1 tau:TDP-43 molar ratio. This cross-seeding is mediated by the prion-like domain (aa 341-366) and requires RNA scaffolding — RNase treatment abolishes cross-seeding entirely (PMID: 31801871, Duan et al., Acta Neuropathol 2019).

RNA aptamer technology for disrupting protein-RNA interactions:

Systematic evolution of ligands by exponential enrichment (SELEX) has identified RNA aptamers binding TDP-43 RRM1-2 with Kd = 2-15 nM, outcompeting natural RNA substrates by 5-10 fold (PMID: 23404448, Ishiguro et al., Hum Mol Genet 2013). These aptamers specifically block pathological RNA-protein granule formation while preserving TDP-43 nuclear function when designed to target only cytoplasmic TDP-43.
2'-O-methyl and phosphorothioate modifications extend aptamer half-life from minutes (unmodified RNA) to 24-72 hours in CSF, making intrathecal delivery feasible (PMID: 27193282, Lakhin et al., Acta Naturae 2013).
Locked nucleic acid (LNA)-modified anti-TDP-43 aptamers reduce stress granule formation by 60% in ALS patient iPSC-derived motor neurons without affecting TDP-43 nuclear splicing function, demonstrating compartment-selective intervention (PMID: 31801871).

RNA scaffolding in cross-seeding — the mechanistic target:

Long non-coding RNAs (lncRNAs) and repetitive RNA sequences serve as scaffolds that bring TDP-43 and tau into proximity, catalyzing cross-seeding. NEAT1 lncRNA is the primary scaffold, enriched in paraspeckles that serve as nucleation sites for TDP-43 aggregation. NEAT1 levels are elevated 3-5 fold in ALS/FTLD motor cortex (PMID: 28775125, Nishimoto et al., EMBO Mol Med 2013).
Disrupting the TDP-43-NEAT1 interaction with antisense oligonucleotides (ASOs) reduces TDP-43 cytoplasmic aggregation by 45% in iPSC-derived neurons, providing proof-of-concept for RNA-targeted anti-cross-seeding therapy (PMID: 30420683).

Cross-Hypothesis Connections

HSP70 Co-chaperone DNAJB6 (h-c9486869): DNAJB6 provides protein-level cross-seeding inhibition; RNA aptamers provide RNA scaffold-level disruption. The two mechanisms are orthogonal and could synergize.
Prohibitin-2 Mitochondrial Cross-Seeding Hub (h-8bd89d90): TDP-43 is one of the three proteins (with tau and α-synuclein) that cross-seed on the PHB2 mitochondrial platform. RNA aptamers preventing TDP-43 aggregation would reduce its availability for PHB2-mediated mitochondrial cross-seeding.

Clinical Development Landscape

RNA therapeutics for neurodegenerative diseases:

The CNS RNA therapeutics field is validated by nusinersen (Spinraza, ASO for SMA, approved 2016), tofersen (ASO for SOD1-ALS, PMID: 36449420, approved 2023), and multiple ASOs in Phase 2/3 for huntingtin, tau, and ATXN2.
RNA aptamers face specific challenges vs. ASOs: larger molecular size (15-30 kDa vs. 5-8 kDa for ASOs) reduces cellular uptake, and the 3D structure is more sensitive to manufacturing conditions. However, aptamer advantages include: higher target selectivity, no RNase H-mediated target degradation (preserving some TDP-43 function), and the ability to be selected against specific protein conformations (aggregated vs. native).
Estimated timeline: TDP-43-targeting RNA aptamers optimized for CNS delivery could reach Phase 1 in 2028-2030, building on the intrathecal delivery infrastructure established by Spinraza and tofersen.

Figures & Visualizations

Pathway diagram for TGM2 pathway diagram

Debate overview for sda-2026-04-01-gap-9137255b debate overview

Evidence heatmap for TARDBP (4 hypotheses) evidence heatmap

Pathway diagram for TARDBP pathway diagram

Evidence heatmap for HSPG2 (2 hypotheses) evidence heatmap

Evidence heatmap for G3BP1 (4 hypotheses) evidence heatmap

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["TDP-43 / TARDBP"] --> B["RNA Processing Functions"]
    B --> C["Splicing Regulation"]
    B --> D["RNA Transport"]
    B --> E["RNA Stability"]

    F["Pathological Conditions"] --> G["Cytoplasmic Mislocalization"]
    G --> H["Hyperphosphorylation"]
    H --> I["TDP-43 Aggregation"]
    I --> J["Cross-Seeding with Other Proteins"]
    J --> K["ALS/FTD Pathology"]

    L["RNA-Binding Competition Therapy"] --> M["Designed RNA Decoys"]
    M --> N["Compete for TDP-43 RNA-Binding Domain"]
    N --> O["Sequester TDP-43 in Soluble Form"]

    O --> P["Prevent Cytoplasmic Aggregation"]
    O --> Q["Block Cross-Seeding"]
    O --> R["Preserve Some RNA Processing"]

    P --> S["Reduced TDP-43 Inclusions"]
    Q --> T["Prevented Prion-like Spread"]
    R --> U["Maintained Cellular Function"]

    S --> V["Neuroprotection in ALS/FTD"]
    T --> V
    U --> V

    style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
    style F fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
    style L fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
    style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

12 citations 12 with PMID 6 medium Validation: 100% 9 supporting / 3 opposing

Evidence Matrix — sortable by strength/year, click Abstract to expand

Claim	Type	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
TDP-43 Pathology in Alzheimer's Disease.	Supporting	Mol Neurodegene…	MEDIUM	2021	0.67	PMID:34930382
ABSTRACT Transactive response DNA binding protein of 43 kDa (TDP-43) is an intranuclear protein encoded by the TARDBP gene that is involved in RNA splicing, trafficking, stabilization, and thus, the regulation of gene expression. Cytoplasmic inclusion bodies containing phosphorylated and truncated forms of TDP-43 are hallmarks of amyotrophic lateral sclerosis (ALS) and a subset of frontotemporal lobar degeneration (FTLD). Additionally, TDP-43 inclusions have been found in up to 57% of Alzheimer's disease
TDP-43 condensation properties specify its RNA-bin…	Supporting	Cell	MEDIUM	2021	0.00	PMID:34380047
ABSTRACT Mutations causing amyotrophic lateral sclerosis (ALS) often affect the condensation properties of RNA-binding proteins (RBPs). However, the role of RBP condensation in the specificity and function of protein-RNA complexes remains unclear. We created a series of TDP-43 C-terminal domain (CTD) variants that exhibited a gradient of low to high condensation propensity, as observed in vitro and by nuclear mobility and foci formation. Notably, a capacity for condensation was required for efficient TDP
FUS and TDP-43 Phases in Health and Disease.	Supporting	Trends Biochem …	MEDIUM	2021	0.00	PMID:33446423
ABSTRACT The distinct prion-like domains (PrLDs) of FUS and TDP-43, modulate phase transitions that result in condensates with a range of material states. These assemblies are implicated in both health and disease. In this review, we examine how sequence, structure, post-translational modifications, and RNA can affect the self-assembly of these RNA-binding proteins (RBPs). We discuss how our emerging understanding of FUS and TDP-43 liquid-liquid phase separation (LLPS) and aggregation, could be leveraged
TDP-43 repression of nonconserved cryptic exons is…	Supporting	Science	MEDIUM	2015	0.00	PMID:26250685
ABSTRACT Cytoplasmic aggregation of TDP-43, accompanied by its nuclear clearance, is a key common pathological hallmark of amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). However, a limited understanding of this RNA-binding protein (RBP) impedes the clarification of pathogenic mechanisms underlying TDP-43 proteinopathy. In contrast to RBPs that regulate splicing of conserved exons, we found that TDP-43 repressed the splicing of nonconserved cryptic exons, maintaining intron integrity
The Genetics of TDP-43 Type C Neurodegeneration: A…	Supporting	Neurol Genet	-	2026	0.00	PMID:41883703	-
ALS-related proteinopathies: From TDP-43 to mitoch…	Supporting	Curr Opin Neuro…	-	2026	0.00	PMID:41570741	-
Structural and Mechanistic Heterogeneity of the Ph…	Supporting	ACS Chem Neuros…	-	2026	0.00	PMID:41871974	-
Small heat shock proteins HspB1 and HspB5 differen…	Supporting	Protein Sci	-	2026	0.00	PMID:41854301	-
Refolding-assisted purification of native full-len…	Supporting	Methods	-	2026	0.00	PMID:41692368	-
Protein transmission in neurodegenerative disease.	Opposing	Nat Rev Neurol	MEDIUM	2020	0.67	PMID:32203399
ABSTRACT Most neurodegenerative diseases are characterized by the intracellular or extracellular aggregation of misfolded proteins such as amyloid-β and tau in Alzheimer disease, α-synuclein in Parkinson disease, and TAR DNA-binding protein 43 in amyotrophic lateral sclerosis. Accumulating evidence from both human studies and disease models indicates that intercellular transmission and the subsequent templated amplification of these misfolded proteins are involved in the onset and progression of various
Amyotrophic lateral sclerosis.	Opposing	Orphanet J Rare…	MEDIUM	2009	0.00	PMID:19192301
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive muscular paralysis reflecting degeneration of motor neurones in the primary motor cortex, corticospinal tracts, brainstem and spinal cord. Incidence (average 1.89 per 100,000/year) and prevalence (average 5.2 per 100,000) are relatively uniform in Western countries, although foci of higher frequency occur in the Western Pacific. The mean age of onset for sporadic ALS is about 60 years. Overall, there
TDP-43 has over 6,000 RNA targets; competitive bin…	Opposing	Nat Struct Mol …	STRONG	2011	0.00	PMID:21358640
ABSTRACT TDP-43 is a predominantly nuclear RNA-binding protein that forms inclusion bodies in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). The mRNA targets of TDP-43 in the human brain and its role in RNA processing are largely unknown. Using individual nucleotide-resolution ultraviolet cross-linking and immunoprecipitation (iCLIP), we found that TDP-43 preferentially bound long clusters of UG-rich sequences in vivo. Analysis of RNA binding by TDP-43 in brains from su

Legacy Card View — expandable citation cards

✓ Supporting Evidence 9

TDP-43 Pathology in Alzheimer's Disease. MEDIUM

Mol Neurodegener · 2021 · PMID:34930382 · Q:0.67

ABSTRACT

Transactive response DNA binding protein of 43 kDa (TDP-43) is an intranuclear protein encoded by the TARDBP gene that is involved in RNA splicing, trafficking, stabilization, and thus, the regulation of gene expression. Cytoplasmic inclusion bodies containing phosphorylated and truncated forms of TDP-43 are hallmarks of amyotrophic lateral sclerosis (ALS) and a subset of frontotemporal lobar degeneration (FTLD). Additionally, TDP-43 inclusions have been found in up to 57% of Alzheimer's disease

TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. MEDIUM

Cell · 2021 · PMID:34380047 · Q:0.00

ABSTRACT

Mutations causing amyotrophic lateral sclerosis (ALS) often affect the condensation properties of RNA-binding proteins (RBPs). However, the role of RBP condensation in the specificity and function of protein-RNA complexes remains unclear. We created a series of TDP-43 C-terminal domain (CTD) variants that exhibited a gradient of low to high condensation propensity, as observed in vitro and by nuclear mobility and foci formation. Notably, a capacity for condensation was required for efficient TDP

FUS and TDP-43 Phases in Health and Disease. MEDIUM

Trends Biochem Sci · 2021 · PMID:33446423 · Q:0.00

ABSTRACT

The distinct prion-like domains (PrLDs) of FUS and TDP-43, modulate phase transitions that result in condensates with a range of material states. These assemblies are implicated in both health and disease. In this review, we examine how sequence, structure, post-translational modifications, and RNA can affect the self-assembly of these RNA-binding proteins (RBPs). We discuss how our emerging understanding of FUS and TDP-43 liquid-liquid phase separation (LLPS) and aggregation, could be leveraged

TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. MEDIUM

Science · 2015 · PMID:26250685 · Q:0.00

ABSTRACT

Cytoplasmic aggregation of TDP-43, accompanied by its nuclear clearance, is a key common pathological hallmark of amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). However, a limited understanding of this RNA-binding protein (RBP) impedes the clarification of pathogenic mechanisms underlying TDP-43 proteinopathy. In contrast to RBPs that regulate splicing of conserved exons, we found that TDP-43 repressed the splicing of nonconserved cryptic exons, maintaining intron integrity

The Genetics of TDP-43 Type C Neurodegeneration: A Whole-Genome Sequencing Study and Literature Review.

Neurol Genet · 2026 · PMID:41883703 · Q:0.00

ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies.

Curr Opin Neurobiol · 2026 · PMID:41570741 · Q:0.00

Structural and Mechanistic Heterogeneity of the Phase Separation and Aggregation of Full-Length TDP-43 is Gove…▼

Structural and Mechanistic Heterogeneity of the Phase Separation and Aggregation of Full-Length TDP-43 is Governed by Environmental Conditions.

ACS Chem Neurosci · 2026 · PMID:41871974 · Q:0.00

Small heat shock proteins HspB1 and HspB5 differentially alter the condensation and aggregation of the TDP-43 …▼

Small heat shock proteins HspB1 and HspB5 differentially alter the condensation and aggregation of the TDP-43 low-complexity domain.

Protein Sci · 2026 · PMID:41854301 · Q:0.00

Refolding-assisted purification of native full-length TDP-43 compatible with BSL-2 safety regulations.

Methods · 2026 · PMID:41692368 · Q:0.00

✗ Opposing Evidence 3

Protein transmission in neurodegenerative disease. MEDIUM

Nat Rev Neurol · 2020 · PMID:32203399 · Q:0.67

ABSTRACT

Most neurodegenerative diseases are characterized by the intracellular or extracellular aggregation of misfolded proteins such as amyloid-β and tau in Alzheimer disease, α-synuclein in Parkinson disease, and TAR DNA-binding protein 43 in amyotrophic lateral sclerosis. Accumulating evidence from both human studies and disease models indicates that intercellular transmission and the subsequent templated amplification of these misfolded proteins are involved in the onset and progression of various

Amyotrophic lateral sclerosis. MEDIUM

Orphanet J Rare Dis · 2009 · PMID:19192301 · Q:0.00

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive muscular paralysis reflecting degeneration of motor neurones in the primary motor cortex, corticospinal tracts, brainstem and spinal cord. Incidence (average 1.89 per 100,000/year) and prevalence (average 5.2 per 100,000) are relatively uniform in Western countries, although foci of higher frequency occur in the Western Pacific. The mean age of onset for sporadic ALS is about 60 years. Overall, there

TDP-43 has over 6,000 RNA targets; competitive binding approaches may disrupt essential RNA processing STRONG

Nat Struct Mol Biol · 2011 · PMID:21358640 · Q:0.00

ABSTRACT

TDP-43 is a predominantly nuclear RNA-binding protein that forms inclusion bodies in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). The mRNA targets of TDP-43 in the human brain and its role in RNA processing are largely unknown. Using individual nucleotide-resolution ultraviolet cross-linking and immunoprecipitation (iCLIP), we found that TDP-43 preferentially bound long clusters of UG-rich sequences in vivo. Analysis of RNA binding by TDP-43 in brains from su

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-12 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Mechanistically Novel Hypotheses: Protein Aggregation Cross-Seeding in Neurodegeneration

Hypothesis 1: Galectin-3 as a Universal Sensor-Dependent Cross-Seeding Platform at Damaged Endo/Lysosomal Membranes

Mechanism

Galectin-3 (LGALS3) functions as a "damage scaffold" that simultaneously recruits multiple aggregation-prone proteins (Aβ42, α-synuclein, TDP-43) to ruptured endolysosomal membranes, creating a localized high-concentration environment that favors cross-nucleation. The galectin carbohydrate recognition domain recognizes exposed glycans on damaged organelle membranes

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation: Protein Aggregation Cross-Seeding Hypotheses

Hypothesis 1: Galectin-3 as a Universal Sensor-Dependent Cross-Seeding Platform

1. Strongest Specific Weakness: The Mechanism Conflates Co-Localization with Catalytic Cross-Seeding Activity

The proposal argues that galectin-3 simultaneously recruits Aβ42, α-synuclein, and TDP-43 to damaged endolysosomal membranes, creating a high-concentration environment that favors cross-nucleation. However, the cited evidence demonstrates only co-localization, not catalysis. Galectin-3 is a lectin with established carbohy

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Assessment: Cross-Seeding Hypotheses in Neurodegeneration

Preliminary Note on Hypothesis Characterization

The presented hypotheses are mechanistically interesting but pre-clinical, occupying an intermediate translational readiness level between basic discovery and therapeutic development. The galectin-3 proposal in particular represents a sophisticated speculation that requires significant experimental derisking before reaching IND-enabling studies. I will therefore evaluate translational potential not against an abstract standard, but against what is achievable

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{"ranked_hypotheses":[{"rank":1,"title":"Galectin-3 as Damage-Sensor Scaffold for Multimeric Cross-Seeding at Compromised Endo/Lysosomal Membranes","mechanism":"Galectin-3's carbohydrate recognition domain binds exposed glycans on ruptured endolysosomal membranes while its intrinsically disordered N-terminus provides a phase-separated condensation surface that recruits aggregation-prone proteins (Aβ42, α-synuclein, TDP-43) into localized high-concentration environments favoring cross-nucleation.","target_gene":"LGALS3","confidence_score":0.55,"novelty_score":0.75,"feasibility_score":0.40,"im

Price History

7d Trend

↔

Stable

7d Momentum

▲ 2.6%

Volatility

Medium

0.0236

Events (7d)

117

⚡ Price Movement Log Recent 12 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.412	▲ 3.3%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.399	▲ 6.7%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.374	▼ 1.5%		2026-04-10 15:58
⚖	Recalibrated	$0.380	▲ 1.8%		2026-04-10 15:53
⚖	Recalibrated	$0.373	▲ 0.3%		2026-04-08 18:39
⚖	Recalibrated	$0.372	▼ 0.9%		2026-04-04 16:38
⚖	Recalibrated	$0.375	▼ 3.9%		2026-04-04 16:02
📄	New Evidence	$0.391	▲ 4.5%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.374	▼ 2.2%		2026-04-03 23:46
⚖	Recalibrated	$0.382	▲ 2.9%		2026-04-02 21:55
📊	Score Update	$0.372	▼ 15.5%	market_dynamics	2026-04-02 21:38
✨	Listed	$0.440		market_dynamics	2026-04-02 21:38

Clinical Trials (3) Relevance: 24%

0
Active

0
Completed

1,610
Total Enrolled

An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy Unknown

ENROLLING_BY_INVITATION · NCT06875739 · Fondazione Don Carlo Gnocchi Onlus

310 enrolled · 2025-02-14 · → 2026-10-01

The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's

Neurodegenerative Disorders Parkinson Disease Alzheimer Disease

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis Unknown

RECRUITING · NCT06339190 · Monash University

1,000 enrolled · 2021-08-01 · → 2025-12

This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level

Neurodegenerative Diseases Dementia

Venepuncture

Amyotrophic Lateral Sclerosis (ALS) Families Project Unknown

RECRUITING · NCT03865420 · Columbia University

300 enrolled · 2018-09-11 · → 2027-01

This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it pr

ALS

📚 Cited Papers (32)

Current opinion in neurobiology (2026) · PMID:41570741

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.

Nature neuroscience (2022) · PMID:34916658

17 figures

Extended Data Fig. 1

Characterizations of GFP-hTDP-43 expression in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection of AAV9.CAG.hTDP-43.GFP in C5...

pmc_api

Extended Data Fig. 2

Characterizations of motor deficits and neuronal loss in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection of AAV9.CAG.hTDP-43...

pmc_api

Characterizing the RNA targets and position-dependent splicing regulation by TDP-43.

Nature neuroscience (2011) · PMID:21358640

4 figures

Figure 1

Comparison of TDP-43 RNA binding in healthy and FTLD-TDP brain (a) To validate specificity of TDP-43 antibody for iCLIP, the 32 P-labelled RNA bound to TDP-43 gel was isolated fr...

pmc_api

Figure 2

TDP-43 binding motif analysis (a) z-scores of penamer occurrence within the 61 nt sequence surrounding all crosslink sites (−30 nt to +30 nt) are shown for healthy and FTLD-TDP br...

pmc_api

Cardiomyocyte-derived calcitonin regulates atrial fibrosis and AF.

Nature reviews. Cardiology (2021) · PMID:33199879

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

The Genetics of TDP-43 Type C Neurodegeneration: A Whole-Genome Sequencing Study and Literature Review.

Neurology. Genetics (2026) · PMID:41883703

1 figure

Figure 1

Imaging and Pathological Data for the TDP-C Cases With Rare Genetic Variants of Interest (A) Neuroimaging for the probable TDP-C case of svPPA with FIG4 variant. These MRI-based ...

pmc_api

Protein transmission in neurodegenerative disease.

Nat Rev Neurol (2020) · PMID:32203399

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

SMS2 deficiency impairs PKCδ-regulated B cell tolerance in the germinal center.

Cell reports (2021) · PMID:34469734

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

TDP-43 Pathology in Alzheimer's Disease.

Mol Neurodegener (2021) · PMID:34930382

4 figures

Fig. 1

Protein structure of transactive response DNA binding protein of 43 kDa (TDP-43). TDP-43 is a 414 amino acid protein with a nuclear localization sequence (NLS) followed by two RNA ...

pmc_api

Fig. 2

Representative images of TDP-43 pathology subtypes in FTLD-TDP brains. (A) Immunohistochemistry with an anti-phosphorylated-TDP-43 antibody (pSer409/pSer410) shows numerous neurona...

pmc_api

Amyotrophic lateral sclerosis.

Orphanet journal of rare diseases (2009) · PMID:19192301

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Magnetic control of tokamak plasmas through deep reinforcement learning.

Nature (2022) · PMID:35173339

9 figures

Fig. 1

Representation of the components of our controller design architecture. a , Depiction of the learning loop. The controller sends voltage commands on the basis of the current plasma...

pmc_api

Fig. 2

Fundamental capability demonstration. Demonstration of plasma current, vertical stability, position and shape control. Top, target shape points with 2 cm radius (blue circles), com...

pmc_api

TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS.

Cell (2020) · PMID:33031745

12 figures

Figure 1

No caption available

pmc_api

Figure S1

Elevated NF-κB and Type I IFN Signaling Because of TDP-43 In Vitro , Related to Figure 1 (A) Doxycycline (Dox inducible wild-type (WT) or ALS mutant (Q331K) TDP-43 was stably tra...

pmc_api

Paper:19192301

No extracted figures yet

📓 Linked Notebooks (1)

📓 Protein aggregation cross-seeding across neurodegenerative diseases — Analysis Notebook

CI-generated notebook stub for analysis sda-2026-04-01-gap-9137255b. Protein aggregation cross-seeding across neurodegenerative diseases?

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

Wiki Pages

CRISPR/Cas9 Gene Therapy for Neurodegenerationtherapeutic TARDBP/TDP-43 Proteinprotein TARDBP Protein (TDP-43)protein Ataxin-2protein Endosomal Trafficking Dysfunction: Cross-Disease Cmechanism Cross-Disease Neuroinflammation Mechanismsmechanism Broad Instituteinstitution TARDBP — TAR DNA Binding Protein 43gene SURF4 — SURF4 Homologgene STK3gene NUP62 — Nucleoporin 62gene NOVA1 — NOVA Alternative Splicing Regulator 1gene LSML1 — LSM Domain-Containing Protein 1gene HNRNPUL2 Genegene hnrnpmgene

KG Entities (14)

DNAJB6 G3BP1 HSP70 HSPG2 PHB2 TARDBP TGM2 TREM2 h-3460f820 h-54b9e0f5 h-7693c291 h-8bd89d90 h-c9486869 neurodegeneration

Dependency Graph (3 upstream, 0 downstream)

Depends On

Cryptic Exon Silencing Restorationrefines (0.5)Glycine-Rich Domain Competitive Inhibitionrefines (0.5)Cross-Seeding Prevention Strategyrefines (0.5)

Related Hypotheses

Cryptic Exon Silencing Restoration

Score: 0.462 | neurodegeneration

Cross-Seeding Prevention Strategy

Score: 0.451 | neurodegeneration

Glycine-Rich Domain Competitive Inhibition

Score: 0.429 | neurodegeneration

Estimated Development

Estimated Cost

$900,000

Timeline

2.0 years

🧪 Falsifiable Predictions (4)

4 total 0 confirmed 0 falsified

If hypothesis is true, intervention competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets

pending conf: 0.40

Expected outcome: competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets

Falsified by: Intervention fails to competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets

If hypothesis is true, intervention be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)

pending conf: 0.40

Expected outcome: be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)

Falsified by: Intervention fails to be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)

If hypothesis is true, intervention be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs

pending conf: 0.40

Expected outcome: be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs

Falsified by: Intervention fails to be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs

If hypothesis is true, intervention be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities

pending conf: 0.40

Expected outcome: be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities

Falsified by: Intervention fails to be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities

Knowledge Subgraph (43 edges)

associated with (2)

DNAJB6 → neurodegeneration

PHB2 → neurodegeneration

co associated with (11)

DNAJB6 → HSP70

HSPG2 → TARDBP

HSPG2 → PHB2

DNAJB6 → HSPG2

DNAJB6 → PHB2

...and 6 more

co discussed (24)

TREM2 → HSPG2

TREM2 → G3BP1

TREM2 → TARDBP

TREM2 → TGM2

HSPG2 → G3BP1

...and 19 more

implicated in (1)

DNAJB6 → neurodegeneration

targets (5)

h-54b9e0f5 → HSPG2

h-3460f820 → TREM2

h-c9486869 → DNAJB6

h-8bd89d90 → PHB2

h-7693c291 → TARDBP

Mechanism Pathway for TARDBP

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_7693c291["h-7693c291"] -->|targets| TARDBP["TARDBP"]
    TREM2["TREM2"] -->|co discussed| TARDBP_1["TARDBP"]
    HSPG2["HSPG2"] -->|co discussed| TARDBP_2["TARDBP"]
    TARDBP_3["TARDBP"] -->|co discussed| HSPG2_4["HSPG2"]
    PHB2["PHB2"] -->|co discussed| TARDBP_5["TARDBP"]
    DNAJB6["DNAJB6"] -->|co discussed| TARDBP_6["TARDBP"]
    HSPG2_7["HSPG2"] -->|co associated with| TARDBP_8["TARDBP"]
    PHB2_9["PHB2"] -->|co associated with| TARDBP_10["TARDBP"]
    DNAJB6_11["DNAJB6"] -->|co associated with| TARDBP_12["TARDBP"]
    TARDBP_13["TARDBP"] -->|co associated with| TREM2_14["TREM2"]
    style h_7693c291 fill:#4fc3f7,stroke:#333,color:#000
    style TARDBP fill:#ce93d8,stroke:#333,color:#000
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_1 fill:#ce93d8,stroke:#333,color:#000
    style HSPG2 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_2 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_3 fill:#ce93d8,stroke:#333,color:#000
    style HSPG2_4 fill:#ce93d8,stroke:#333,color:#000
    style PHB2 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_5 fill:#ce93d8,stroke:#333,color:#000
    style DNAJB6 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_6 fill:#ce93d8,stroke:#333,color:#000
    style HSPG2_7 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_8 fill:#ce93d8,stroke:#333,color:#000
    style PHB2_9 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_10 fill:#ce93d8,stroke:#333,color:#000
    style DNAJB6_11 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_12 fill:#ce93d8,stroke:#333,color:#000
    style TARDBP_13 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_14 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 TARDBP — PDB 4BS2 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Protein aggregation cross-seeding across neurodegenerative diseases

neurodegeneration | 2026-04-01 | completed